Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease
NCT00431249
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Hemodialysis Patients
Peripheral Vascular Disease
Interventions
DRUG:
Cilostazol
Sponsor
Tungs' Taichung Metroharbour Hospital